Incyte | INCY - Ordinary Share Capital

Stock Price
94.65
Daily Change
-0.82 -0.86%
Monthly
2.62%
Yearly
59.99%
Q2 Forecast
92.62

Incyte reported $198.46M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Agenus USD 35.32M 2.51M Dec/2025
Agios Pharmaceuticals USD 58.45M 169K Dec/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Amgen USD 539M 1000K Dec/2025
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Exelixis USD 268.1M 2.03M Sep/2025
Gilead Sciences USD 1.24B 1000K Dec/2025
Incyte USD 198.46M 2.33M Dec/2025
Ionis Pharmaceuticals USD 161.97M 836K Dec/2025
MacroGenics USD 63.32M 60K Dec/2025
Merck USD 2.49B 15.79M Sep/2025
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Novartis USD 1.91B 10.64M Dec/2025
Novartis USD 1.91B 10.64M Dec/2025
Pfizer USD 5.69B 1000K Sep/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Sarepta Therapeutics USD 104.96M 196K Dec/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025